Patents Examined by Esther L. Kepplinger
  • Patent number: 5292667
    Abstract: A monoclonal antibody which binds preferentially to colonic glycoproteins of cells of persons having ulcerative colitis, compared to colonic glycoproteins of cells of persons not having ulcerative colitis, and diagnostic and therapeutic uses thereof.
    Type: Grant
    Filed: March 20, 1991
    Date of Patent: March 8, 1994
    Assignee: The General Hospital Corporation
    Inventors: Daniel K. Podolsky, Deborah A. Fournier
  • Patent number: 5292642
    Abstract: The present disclosure relates to a new lymphokine molecule, referred to as Monocyte Cytotoxicity Inducing Factor (MCF), and its use as in cancer and other types of therapy. The disclosure also relates to antibodies that immunologically recognize MCF, as well as to the use of such antibodies in detecting the presence of MCF and biologic samples. The disclosure further relates to the development of novel Sezary cell hybridomas which secrete MCF and thereby provide a ready source for MCF isolation and purification.Sezary's Syndrome is a leukemic proliferation of OKT4+ lymphocytes. Sezary cells were isolated by differential centrifugation and fused to CEM.8aza.sup.r.C, an HGPRTase lacking clone of CEM. The hybrid cells were studied for their ability to produce soluble mediators of human monocyte cytotoxicity. The product of a single clone, FtF3, which bore the surface phenotype of Sezary cells, was characterized.
    Type: Grant
    Filed: December 7, 1990
    Date of Patent: March 8, 1994
    Assignee: Board of Regents, The University of Texas System
    Inventor: C. Michael Jones
  • Patent number: 5290678
    Abstract: A diagnostic test kit is disclosed for assessing whether patient chest pain is cardiac in origin and for differentiating between unstable angina and myocardial infarction at early onset of patient chest pain. The test kit comprises a receptacle for receiving and retaining a sample of blood or serum of the patient and at least three monoclonal or polyclonal antibodies suspended on a carrier. Each antibody is complementary to a different protein released by the heart muscle during early stages of a myocardial infarction and has corresponding reagents which are independently responsive to each antibody reacting the complementary protein. The combined response of reagents indicates the diagnostic condition of the patient.
    Type: Grant
    Filed: May 3, 1991
    Date of Patent: March 1, 1994
    Assignee: Spectral Diagnostics Inc.
    Inventor: George Jackowski
  • Patent number: 5288614
    Abstract: In order to aid in the detection of malignant diseases the sample of a body fluid is incubated with at least two receptors R.sub.1 and R.sub.2 in which a signal change is produced by binding of at least the receptors R.sub.1 and R.sub.2 to the substance to be detected in the sample solution and in which one of the two receptors contains a monoclonal antibody which binds to the amino acid sequence 311 to 335 of cytokeratin 19 and the other receptor contains a monoclonal antibody which binds to the amino acid sequence 346 to 359 of cytokeratin 19 and the signal change in the sample caused by the binding is determined.
    Type: Grant
    Filed: July 23, 1991
    Date of Patent: February 22, 1994
    Assignee: Boehringer Mannheim GmbH
    Inventors: Heinz Bodenmuller, Andreas Dessauer
  • Patent number: 5284777
    Abstract: A method and kit for the isolation and quantitation of glycated hemoglobin and other glycated proteins, specifically albumin, from a single sample of whole blood. Glycated hemoglobin is calculated from an eluate resulting from the contact of the whole blood hemolysate with a boronated resin. Glycated albumin and other plasma proteins are calculated using immunoturbidimetry, resulting from reaction between a buffered antibody solution and the albumin or other protein in the previous eluate.
    Type: Grant
    Filed: March 4, 1991
    Date of Patent: February 8, 1994
    Assignee: Isolab, Inc.
    Inventors: Murray A. Rosenthal, David R. Hocking
  • Patent number: 5284751
    Abstract: An antibody that immunoreacts with a ligand-induced binding site (LIBS) on GPIIIa, and particularly, a LIBS induced in a platelet-associated GPIIb-IIIa/fibrinogen complex is disclosed. Further disclosed are diagnostic systems and methods for assaying LIBS-containing platelets in a vascular fluid sample using the antibodies of the invention.
    Type: Grant
    Filed: October 5, 1989
    Date of Patent: February 8, 1994
    Assignee: The Scripps Research Institute
    Inventors: Andrew L. Frelinger, III, Edward F. Plow, Mark H. Ginsberg
  • Patent number: 5281517
    Abstract: A method and apparatus are provided for selecting and analyzing a subpopulation of cells or cell objects for a certain parameter such as DNA using image analysis means. The cells are first stained with an alkaline phosphatase technique including a monoclonal antibody specific to a protein in at least one of the cell's cytoplasm or on a cell membrane, thereby marking any cells including the protein as to type. A second staining of the DNA in the nucleus is accomplished by a Feulgen technique that destroys the cell cytoplasm. After the staining and marking, the cells may then be gated using the image analysis means on the visual parameter such as colored DNA or colored antigen into a subpopulation that is to be measured. The selected cells may then be examined by digital image processing and measured for a parameter such as a true actual measurement of DNA in picograms. A quantitation of the measured parameter may be generated and provided.
    Type: Grant
    Filed: February 5, 1992
    Date of Patent: January 25, 1994
    Assignee: Cell Analysis Systems, Inc.
    Inventors: James W. Bacus, Robert J. Marder
  • Patent number: 5279937
    Abstract: A macroglobulin is used to improve the signal-to-background ratio in an affinity binding assay employing a proteinase (or precursor) as a label. The macroglobulin entraps unbound labeled reagent, thereby reducing its signal generating activity, relative to that of the affinity complex.
    Type: Grant
    Filed: April 30, 1992
    Date of Patent: January 18, 1994
    Assignee: DeTechnology Canada
    Inventor: Gerald E. Rowe
  • Patent number: 5279942
    Abstract: The invention provides a process and products for the detection of the C peptide of relaxin in the body fluids of animals, as a positive indication of pregnancy. The invention may employ monoclonal antibodies generated to various epitopes on the C peptide.
    Type: Grant
    Filed: February 6, 1992
    Date of Patent: January 18, 1994
    Assignee: International Canine Genetics, Inc.
    Inventor: Andrew H. Kuniyuki
  • Patent number: 5279941
    Abstract: Methods are provided for detecting receptivity of mammalian endometrium to embryo implantation comprising obtaining a sample of the endometrium, contacting the endometrium with a monoclonal antibody for .beta..sub.3 integrin and detecting .beta..sub.3 integrin in the endometrium. The invention also provides for methods of diagnosing infertility in a mammal and methods of detecting the window of embryo implantation in endometrium. Methods of in vitro fertilization, methods of preventing embryo implantation and a method of monitoring endometrial maturation are also within the scope of the present invention. The present invention is also directed to contraceptives. Diagnostic kits useful in the practice of the methods of the invention are also provided.
    Type: Grant
    Filed: June 12, 1992
    Date of Patent: January 18, 1994
    Assignee: Trustees of the University of Pennsylvania
    Inventor: Bruce Lessey
  • Patent number: 5277589
    Abstract: For the determination of antibodies based on an immunoassay technique by incubation with at least three receptors R.sub.1, R.sub.2 and R.sub.3 which are present dissolved in a liquid phase and of which R.sub.1 is an antigen which is capable of being specifically bound to the antibody to be determined, R.sub.2 mediates the binding to the solid phase and R.sub.3 carries a label, separation of the complex which forms from the solution by binding to a solid phase and measurement of the label in one of the phases, a conjugate is used as the receptor R.sub.2 composed of a receptor capable of specific binding to R.sub.1 and a substance S.sub.1, which can be specifically bound, and a conjugate of a receptor which can specifically bind to R.sub.1 and a label is used as R.sub.3, wherein the immobilization of the complex which forms is mediated by binding to a component of the solid phase which can specifically bind S.sub.1.
    Type: Grant
    Filed: March 1, 1991
    Date of Patent: January 11, 1994
    Assignee: Boehringer Mannheim GmbH
    Inventors: Urban Schmitt, Wolfgang Rudinger, Gertraud Ehrlich-Weinreich
  • Patent number: 5278045
    Abstract: This invention is directed to a composition comprising a substantially purified protein which enhances endogenous stimulus-induced neurotransmitter release, said neurotransmitter being selected from the group consisting of acetylcholine, dopamine or serotonin, said protein having a binding affinity constant of at least 2.9.+-.0.8 nM for tritiated 3,3-bis(4-pyridinylmethyl)-1-phenylindolin-2-one as determined by a Scatchard analysis, and said protein being trypsin sensitive and phospholipase C insensitive.
    Type: Grant
    Filed: February 28, 1990
    Date of Patent: January 11, 1994
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventor: Sang W. Tam
  • Patent number: 5273877
    Abstract: Disclosed are non-histological methods for determining the presence in a sample of a preselected cell type such as a malignant or genetically defective cell, or cell nucleus debris from such cells. The methods involve determination of an intranuclear matrix protein, the mRNA encoding that protein, or matrix protein associated DNA or RNA which acts as a marker for the preselected cell type, the presence of which indicates the presence of the cell type in the test sample. The intranuclear matrix marker protein or nucleotide are detected by hybridization, immunoassay, or other known means.
    Type: Grant
    Filed: June 30, 1988
    Date of Patent: December 28, 1993
    Assignee: Massachusetts Institute of Technology
    Inventors: Edward G. Fey, Sheldon Penman
  • Patent number: 5272055
    Abstract: A method for diagnosing a neurological disease comprising detecting a neurological disease-specific biochemical marker macromolecule within a sample of extracted cerebral spinal fluid is disclosed. In particular, a radioactively labeled photoaffinity probe is used to diagnose a neurological disease. For instance, Alzheimer's disease can be diagnosed by detecting a disease-specific protein having a molecular weight of about 42,000 daltons, i.e., glutamine synthetase.
    Type: Grant
    Filed: December 24, 1991
    Date of Patent: December 21, 1993
    Assignee: The University of Kentucky Research Foundation
    Inventor: Boyd Haley
  • Patent number: 5270166
    Abstract: The present invention relates to immunoassay methods for detecting and measuring the amount of an analyte in a sample by means of generic anti-hapten antibodies. Also disclosed are multi-analyte immunoassay methods. Reagents, devices, and kits using the anti-hapten antibodies are also disclosed. The present invention also relates to dyed erythrocytes, preferably fixed, which are coated with antibodies. Also disclosed is the use of these dyed erythrocytes in agglutination assays to detect and measure the presence of an analyte in a sample. The analyte can be a hapten, an antigen, or an antibody. Also included are agglutination assays, compositions and kits using these dyed and coated erythrocytes.
    Type: Grant
    Filed: March 30, 1992
    Date of Patent: December 14, 1993
    Assignee: Abbott Laboratories
    Inventors: Robert Parsons, Robert Kowal, Vincent T. Yue
  • Patent number: 5270164
    Abstract: A process is disclosed for the enhancement of the chemiluminescence of enzyme-triggered 1,2-dioxetanes detectable within a sample. The process comprises first providing a solid support having sample disposed thereon and suitably treated with a solution including enzyme-triggered 1,2-dioxetanes. The solid support is next dried and optionally heated either simultaneously with drying or thereafter. The steps of drying and/or heating are conducted either prior to or simultaneously with detection.
    Type: Grant
    Filed: March 1, 1993
    Date of Patent: December 14, 1993
    Assignee: E. I. Du Pont de Nemours and Company
    Inventors: Lynne E. Anderson, Robert K. Kobos, Shay E. Polsky
  • Patent number: 5266313
    Abstract: Raccoon poxvirus, an organism that may be indigenous in nature, is established as a suitable substrate for insertion and expression of nucleotide coding sequence of heterolgous organisms. Two infectious raccoon poxvirus recombinants for expressing rabies virus surface spike glycoprotein (G) were produced by homologous recombination between raccoon poxvirus DNA and chimeric plasmids previously used for production of vaccinia virus recombinants by thymidine kinase insertional inactivation. Raccoons that were fed polyurethane baits loaded with raccoon poxvirus recombinant quickly developed high levels of rabies virus neutralizing antibodies and were protected when challenged with an otherwise lethal dose of raccoon rabies street virus. Dogs developed rabies virus neutralizing antibodies after feeding a vectored raccoon poxvirus recombinant in contrast to feeding a vaccinia: G recombinant that induced no rabies neutralizing antibodies.
    Type: Grant
    Filed: February 3, 1992
    Date of Patent: November 30, 1993
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Joseph J. Esposito, George M. Baer
  • Patent number: 5266498
    Abstract: An assay for an analyte in a test sample that uses a ligand binding reaction between the analyte and a specific binding member or a binding member pair that includes one binding member having a Raman active reporter. The analyte can be assayed by measurement of the Raman scattering signal of the Raman-active reporter. The Raman scattering signal can be either a noon-enhanced Raman scattering signal or a Raman scattering signal that is enhanced by a surface capable of enhancing that Raman scattering signal.
    Type: Grant
    Filed: November 7, 1991
    Date of Patent: November 30, 1993
    Assignee: Abbott Laboratories
    Inventors: Peter J. Tarcha, Thomas E. Rohr, Therese Cotton
  • Patent number: 5264344
    Abstract: There is disclosed a method of culturing cells which produce products and identifying the thereby produced products, characterized in that the cells are cultured on the surface of a quantity of growth medium, which surface has been divided into a plurality of growth areas thereby limiting the amount of growth-medium which is available to the cells so that these reach metabolic stage in which said products are produced, and identifying the thereby produced products by an in situ screening procedure.
    Type: Grant
    Filed: November 1, 1991
    Date of Patent: November 23, 1993
    Assignee: University of Leicester
    Inventor: Peter H. A. Sneath
  • Patent number: 5264556
    Abstract: The present invention relates to an anti-idiotypic monoclonal antibody raised against a mouse monoclonal antibody or fragments thereof specific to at least one diarrhetic shellfish poisoning toxin selected from the group consisting of okadaic acid and derivatives thereof. The anti-idiotypic antibody is characterized by reacting only with antibodies to okadaic acid and derivatives thereof but not with antibodies directed against any other compounds. The anti-idiotypic antibody is further characterized by being an internal image of okadaic acid and derivatives thereof. A hybridoma producing an anti-idiotypic antibody in accordance with the present invention has been deposited at the ATCC under accession number HB 10768. Competitive solid-phase assays for determining the amount of okadaic acid and derivatives thereof in marine samples are also provided in accordance with the present invention.
    Type: Grant
    Filed: March 27, 1992
    Date of Patent: November 23, 1993
    Assignee: Rougier Inc.
    Inventors: Hanna Sikorska, William S. Shestowsky